Is the US bio­phar­ma in­dus­try head­ed for a turn­ing point in 2017?

Three months ago, Brent Saun­ders fired a shot across the bow of the USS Big Phar­ma, pledg­ing to lim­it Al­ler­gan’s an­nu­al price in­crease on its port­fo­lio drugs to no more than sin­gle-dig­it per­cent­age hikes each year. On Mon­day, the new US pres­i­dent of di­a­betes spe­cial­ist No­vo Nordisk took that pledge. And 2017 is shap­ing up as a po­ten­tial turn­ing point in the heat­ed pub­lic ar­gu­ment over drug prices in the US.

Endpoints Premium

This article is for premium subscribers only

Upgrade to a premium subscription plan for unlimited access, and join our community of key biopharma players.